LAUSR

PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?

Sign Up to like & get
recommendations!
2 Published in 2022 at "Biomedicines"

DOI: 10.3390/biomedicines10123041

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic and the most common cause of chronic liver disease worldwide. It consists of a spectrum of liver disorders ranging from simple steatosis to NASH which predisposes… read more here.

Keywords: new therapeutic; ppar; epigenetic drugs; driver seat ... See more keywords